Price movements seen among recently-launched generics in the UK do not always reflect changes in reimbursement prices, according to the latest figures from WaveData.

As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.

An IQVIA report dives into how technology can facilitate a digital future for value added medicines, while discussing the market size, opportunities, scope of growth and challenges for this emerging sector in healthcare.

In this podcast discussion, Generics Bulletin’s David Wallace talks to Informa Pharma Consulting’s Duncan Emerton about Celltrion’s CHMP nod for subcutaneous Remsima, the product’s imminent approval and launch, and what it means for the future of biosimilars.

UK concession prices have a history of often failing to keep up with rising prices in the marketplace. However, the latest figures from WaveData suggest that even when prices are falling, concessions can sometimes struggle to compensate independent pharmacists at an adequate price level.

Indian credit rating agency ICRA has forecast that the country’s pharmaceutical industry will remain on a steady 11%-13% growth path this fiscal year, underpinned by healthy domestic demand, new launches and market share gains.